Research Article Open Access

The Effectiveness of Cholecalciferol Addition at Improving Psychosis Symptoms in Amphetamine-Type Stimulant (ATS) Users

Authors

Adhayani Lubis
Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
|
Aznan Lelo
Department of Pharmacology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
|
CORRESPONDING AUTHOR
Dina Keumala Sari
Department of Nutrition, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
|
Diah S. Utami
Indonesia National Narcotics Board, Republic of Indonesia Addict, anxiety, cognitive function, drugs, vitamin D deficiency
Published on: January 15, 2020
DOI 10.3923/pjn.2020.44.50
PDF

Abstract

Background and Objectives: Cholecalciferol plays an important role in the development of brain function and neuropsychiatric disorders, especially psychological disorders. The objective of this study was to observe the differencesin25(OH)D serum levels and Brief Psychiatric Rating Scale (BPRS) scores in individuals who use amphetamine-type stimulants (ATSs) after receiving supplementation with cholecalciferol 1000 IU per day. Materials and Methods: This study had a pre and post-test design with consecutive sampling. Cholecalciferol 1000 IU per day was given to 25 ATS users (intervention/I group), while the other 25 individuals, who composed the control group (C group), did not receive any cholecalciferol supplementation for 42 days. On laboratory tests, the serum level of 25(OH)D is categorized as normal if it is within 54-90 ng mL–1. Psychosis was evaluated with the BPRS questionnaire. Results: There was a significant difference in the serum level of 25(OH)D after the intervention between the groups (I group: 23.37±4.20; C group: 20.33±4.04; p = 0.012) and the increase in the serum level of 25(OH)D was greater in the I group than that of the C group. The result also showed a significant difference in BPRS score after the intervention between the groups [I group: 25(24-27); C group: 27(26-29); p<0.001]. The decrease in the BPRS score in the I group was larger than that in the C group. Conclusion: The administration of cholecalciferol 1000 IU per day increased the 25(OH)D serum level and cholecalciferol supplementation in subjects using ATSs led to a significant reduction in the BPRS score.

Keywords:

Addict, anxiety, cognitive function, drugs, vitamin D deficiency

Article Metrics

155 Abstract Views
173 File Views
0 Downloads

License

Copyright (c) 2020 The Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Article Citation Metrics

Find The Effectiveness of Cholecalciferol Addition at Improving Psychosis Symptoms in Amphetamine-Type Stimulant (ATS) Users on PlumX

How to Cite

Lubis, A., Lelo, A., Sari, D. K., & Utami, D. S. (2020). The Effectiveness of Cholecalciferol Addition at Improving Psychosis Symptoms in Amphetamine-Type Stimulant (ATS) Users. Pakistan Journal of Nutrition, 19(2), 44–50. https://doi.org/10.3923/pjn.2020.44.50
Crossref
Scopus
Google Scholar
Europe PMC

References

1.
Thurn, D., E. Kuntsche, J.A. Weber and J. Wolstein, 2017. Development and validation of the amphetamine-type stimulants motive questionnaire in a clinical population. Front. Psychiatry, Vol. 8.
2.
United Nations Office on Drugs and Crime, 2017. World Drug Report: Executive Summary, Conclusions and Policy Implications. United Nations Austria.
3.
Hsieh, J.H., D.J. Stein and F.M. Howells, 2014. The neurobiology of methamphetamine induced psychosis. Front. Hum. Neurosci., Vol. 8.
4.
United Nations Office Drug and Crime, 2013. Patterns and Trends of Amphetamine-Type Stimulants and Other Drugs: Challenges for Asia and The Pacific. United Nations Office Drug and Crime Research.
5.
Triswara, R. and N. Carolia, 2017. Gangguan fungsi kognitif akibat penyalahgunaan amfetamin. Med. J. Lampung Univ., 7: 49-53.
6.
Medscape, 2017. Amphetamine-related psychiatric disorders. http://emedicine.medscape.com/article/289973-overview.
7.
Sari, D.K., Z.Z. Tala, S. Lestari, S.V. Hutagalung and R.A. Ganie, 2017. Vitamin D receptor gene polymorphism among Indonesian women in North Sumatera. Asian J. Clin. Nutr., 9: 44-50.
8.
Sari, D.K., Z.Z. Tala, S. Lestari, S.V. Hutagalung and R.A. Ganie, 2017. Lifestyle differences in rural and urban areas affected the level of vitamin D in women with single nucleotide polymorphism in North Sumatera. Asian J. Clin. Nutr., 9: 57-63.
9.
Sari, D.K., Z.Z. Tala, S. Lestari, S.V. Hutagalung and R.A. Ganie, 2017. Body mass index but not 25(OH)D serum is associated with bone mineral density among Indonesian women in North Sumatera: A cross sectional study. Asian J. Clin. Nutr., 9: 37-43.
10.
Koutkia, P., T.C. Chen and M.F. Holick, 2001. Vitamin D intoxication associated with an over-the-counter supplement. N. Engl. J. Med., 345: 66-67.
11.
McGrath, J.J., T.H. Burne, F. Féron, A. Mackay-Sim and D.W. Eyles, 2010. Developmental vitamin D deficiency and risk of schizophrenia: A 10-year update. Schizophr. Bull., 36: 1073-1078.
12.
Menkes, D.B., K. Lancaster, M. Grant, R.W. Marsh, P. Dean and S.A. du Toit, 2012. Vitamin D status of psychiatric inpatients in New Zealand’s Waikato region. BMC Psychiatry, Vol. 12.
13.
Sotodeh-Asl, N., M.R. Tamadon, F. Malek and M. Zahmatkesh, 2014. Vitamin D deficiency and psychological disorders. J. Parathyr. Dis., 2: 21-25.
14.
Eyles, D.W., F. Feron, X. Cui, J.P. Kesby and L.H. Harms et al., 2009. Developmental vitamin D deficiency causes abnormal brain development. Psychoneuroendocrinology, 34: S247-S257.
15.
Eserian, J.K., 2013. Vitamin D as an effective treatment approach for drug abuse and addiction. J. Med. Hypotheses Ideas, 7: 35-39.
16.
Szigeti, V., 2016. Vitamin D levels in patients with psychosis: A marker of burden of care? Örebro University School of Medicine Degree project, 30 ETCS. http://www.diva-portal.org/smash/get/diva2:905907/FULLTEXT01.pdf.
17.
BNN., 2017. Kerja bersama perang melawan narkoba. Badan Narkotika Nasional, Jakarta. https://docplayer.info/71355248-Press-release-akhir-tahun-2017-kerja-bersama-perang-melawan-narkoba.html.
18.
Bech, P., M. Kastrup and O.J. Rafaelsen, 1986. Mini-compendium of rating scales for states of anxiety, depression, mania, schizophrenia with corresponding DSM—III syndromes. Acta Psychiatr. Scand., Vol. 73, No. 326, Suppl.
19.
Yüksel, R.N., N. Altunsoy, B. Tikir, M.C. Külük and K. Unal et al., 2014. Correlation between total vitamin D levels and psychotic psychopathology in patients with schizophrenia: therapeutic implications for add-on vitamin D augmentation. Ther. Adv. Psychopharmacol., 4: 268-275.
20.
Hendoiee, N., F. Sheikhmoonesi, M. Zarghami, S. Mamashli and J.Y. Charati et al., 2016. Effectiveness of vitamin D Supplement therapy in chronic stable schizophrenic male patients: A randomized controlled trial. Iran. J. Pharm. Res., 15: 941-950.
21.
Pirnia, B., F. Givi, R. Roshan, K. Pirnia and A.A. Soleimani, 2016. The cortisol level and its relationship with depression, stress and anxiety indices in chronic methamphetamine-dependent patients and normal individuals undergoing inguinal hernia surgery. Med. J. Islam Repub Iran, 30: 679-687.
22.
Brannon, P.M., E.A. Yetley, R.L. Bailey and M.F. Picciano, 2008. Overview of the conference vitamin D and health in the 21st century: An update. Am. J. Clin. Nutr., 88: 483S-490S.
23.
Holick, M.F., N.C. Binkley, H.A. Bischoff-Ferrari, C.M. Gordon and D.A. Hanley et al., 2011. Evaluation, treatment and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab., 96: 1911-1930.
24.
Itzhaky, D., D. Amital, K. Gorden, A. Bogomolni, Y. Arnson and H. Amital, 2012. Low serum vitamin D concentrations in patients with schizophrenia. Isr. Med. Assoc. J., 14: 88-92.
25.
Patrick, R.P. and B.N. Ames, 2015. Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: relevance for ADHD, bipolar disorder, schizophrenia, and impulsive behavior. FASEB J., 29: 2207-2222.
26.
Bramness, J.G., Ø.H. Gundersen, J. Guterstam, E.B. Rognli and M. Konstenius et al., 2012. Amphetamine-induced psychosis - A separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry, Vol. 12.
27.
Wemm, S.E. and R. Sinha, 2019. Drug-induced stress responses and addiction risk and relapse. Neurobiol. Stress, Vol. 10.
28.
Holick, M.F., 2005. Vitamin D for health and in chronic kidney disease. Semin. Dial., 18: 266-275.
29.
Holick, M.F., 2007. Vitamin D deficiency. N. Engl. J. Med., 357: 266-281.